Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 211789, held by Pharmazone. Carisoprodol.
As of Nov 16, 2026, ANDA 211789 (Carisoprodol), held by Pharmazone, was first approved by FDA on Oct 20, 2021, with 0 approved supplements and 0 published complete response letters.
Carisoprodol Tablets, USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol Tablets, USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 20, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters